The end of trajectory in pharma. A case study on Aventis, Merck & Co, GSK

Adam Leaver and Matthieu Montalban

Post-Print from HAL

Date: 2006-10-20
References: Add references at CitEc
Citations:

Published in 2006

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-00153443

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().